RAPT Therapeutics Inc.

RAPT | NASDAQ

Price Alert Chart Builder DCF Calculator

$58.01

$0 (+0.01%)

At close: Mar 6, 2026, 9:30 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.01%

(1D)

Rating

Updated: Mar 19, 2026

11.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $1.61B

1D Range

58.01 58.01

52W Range

5.67 58.02

Valuation (TTM)

PE -5.24

PB 10.58

EV/EBITDA -13.45

Valuation (NTM)

Forward PE N/A

Forward PEG -1.77

Price Target $44.60

Cash Flow

FCF Yield -5.4%

SBC Adj. FCF Yield -6.6%

SBC Impact -21.7%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y -150.0% | -82.8%

Dil EPS 3Y | 5Y 31.9% | 7.8%

FCF 3Y | 5Y 3.5% | -11.3%

Returns

ROA -31.6%

ROE -31.8%

ROIC -37.6%

Financial Health

Net Cash

$154.75M

Current Ratio 12.04

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet need...

Sector Healthcare

Industry Biotechnology

Employees 67

IPO Date Oct 30, 2019

Website www.rapt.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Hold

Price Target

$58

Downside

-0.02%

Buy (1)

Hold (5)

Sell (0)

Analyst Details ➞